Efficacy of IV Fluid Warmer for the Prevention of Hypothermia
Effect of Intravenous Fluid Warmer on Prevention of Hypothermia in Laparoscopic Gastrointestinal Cancer Surgeries During General Anesthesia
1 other identifier
interventional
84
1 country
1
Brief Summary
This study focuses on the importance of the maintenance of body temperature during the surgeries. This study involves the comparison of 2 groups, one receiving warm fluids while the other group receiving room temperature fluids during surgeries.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 2, 2025
CompletedFirst Submitted
Initial submission to the registry
September 13, 2025
CompletedFirst Posted
Study publicly available on registry
September 25, 2025
CompletedSeptember 25, 2025
March 1, 2025
6 months
September 13, 2025
September 23, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
hypothermia
Prevention of hypothermia
5-6 months
Study Arms (2)
Hotline
EXPERIMENTALThese patients had fluid via hotline.
Placebo
PLACEBO COMPARATORReceived fluid at room temperature.
Interventions
This study involves the comparison of 2 groups, one receiving warm fluids while the other group receiving room temperature fluids during surgeries.
Eligibility Criteria
You may qualify if:
- Age 18-60 years,
- ASA I-II,
- both Male \& female,
- elective gastrointestinal cancer surgery -
You may not qualify if:
- Preoperative core temperature greater than 37.2,
- severe endocrine respiratory \& cardiovascular disease. -
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shaukat Khanam Memorial Cancer Hospital LAHORE
Lahore, Punjab Province, 54000, Pakistan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 13, 2025
First Posted
September 25, 2025
Study Start
March 1, 2025
Primary Completion
August 15, 2025
Study Completion
September 2, 2025
Last Updated
September 25, 2025
Record last verified: 2025-03